Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

SmithKline planning Famvir NDA for treatment of multiviral infections in immunocompromised patients.

  • News

Executive Summary

SMITHKLINE BEECHAM FAMVIR NDA FOR MULTIVIRAL INFECTIONS IN IMMUNOCOMPROMISED patients will be filed soon, SB Chief Operating Officer Jean-Pierre Garnier, PhD, indicated at a recent Alex. Brown health care conference in Baltimore. Garnier highlighted use in immunocompromised patients as a significant difference between Famvir (famciclovir) and Glaxo Wellcome's Valtrex (valacyclovir).

Table

View full table

Tags:
Latest Headlines

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

US FDA Developing Model Master File System To Grow Modeling, Simulation Field

US FDA May User Fee Preview: Vaccines, Gene Therapy, And Double Oncologics

Pharma’s IRA Complaints Find Sympathetic Ear In US Appeals Court But Near-Term Relief Unlikely

See All
UsernamePublicRestriction

Register

PS030342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By